1. Home
  2. MRCC vs ACRV Comparison

MRCC vs ACRV Comparison

Compare MRCC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRCC
  • ACRV
  • Stock Information
  • Founded
  • MRCC 2011
  • ACRV 2018
  • Country
  • MRCC United States
  • ACRV United States
  • Employees
  • MRCC N/A
  • ACRV N/A
  • Industry
  • MRCC Investment Managers
  • ACRV Medicinal Chemicals and Botanical Products
  • Sector
  • MRCC Finance
  • ACRV Health Care
  • Exchange
  • MRCC Nasdaq
  • ACRV Nasdaq
  • Market Cap
  • MRCC 174.8M
  • ACRV 170.3M
  • IPO Year
  • MRCC 2012
  • ACRV 2022
  • Fundamental
  • Price
  • MRCC $8.47
  • ACRV $5.78
  • Analyst Decision
  • MRCC Strong Buy
  • ACRV Strong Buy
  • Analyst Count
  • MRCC 1
  • ACRV 5
  • Target Price
  • MRCC $9.00
  • ACRV $22.40
  • AVG Volume (30 Days)
  • MRCC 62.8K
  • ACRV 52.8K
  • Earning Date
  • MRCC 03-10-2025
  • ACRV 11-13-2024
  • Dividend Yield
  • MRCC 11.81%
  • ACRV N/A
  • EPS Growth
  • MRCC 298.01
  • ACRV N/A
  • EPS
  • MRCC 0.60
  • ACRV N/A
  • Revenue
  • MRCC $62,007,000.00
  • ACRV N/A
  • Revenue This Year
  • MRCC N/A
  • ACRV N/A
  • Revenue Next Year
  • MRCC N/A
  • ACRV N/A
  • P/E Ratio
  • MRCC $14.11
  • ACRV N/A
  • Revenue Growth
  • MRCC N/A
  • ACRV N/A
  • 52 Week Low
  • MRCC $6.97
  • ACRV $3.19
  • 52 Week High
  • MRCC $8.80
  • ACRV $11.90
  • Technical
  • Relative Strength Index (RSI)
  • MRCC 55.41
  • ACRV 43.36
  • Support Level
  • MRCC $8.30
  • ACRV $5.36
  • Resistance Level
  • MRCC $8.80
  • ACRV $6.00
  • Average True Range (ATR)
  • MRCC 0.22
  • ACRV 0.54
  • MACD
  • MRCC 0.00
  • ACRV -0.02
  • Stochastic Oscillator
  • MRCC 52.86
  • ACRV 24.73

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: